Efficacy of solifenacin in patients with severe symptoms of overactive bladder: A pooled analysis

Current Medical Research and Opinion

Volumn 22, Issue 1, 2006, Pages 41-48

  Millard, Richard J ^a,c   Halaska, M ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CHARLES UNIVERSITY   (Czech Republic)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Incontinence; Overactive bladder; Severity; Solifenacin

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SOLIFENACIN;

AGE DISTRIBUTION; ANALYSIS OF COVARIANCE; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; NAUSEA; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; STATISTICAL ANALYSIS; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; URINE VOLUME; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III; CONTROLLED CLINICAL TRIALS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PLACEBOS; POPULATION; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 30844469073     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X74907     Document Type: Article

References (18)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002;187:116-26
2. Diokno AC. Epidemiology and psychosocial aspects of incontinence. Urol Clin North Am 1995;22:481-5
3. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 2001;87:760-6
4. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
5. Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7:455-63
6. Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001;57:1044-50
7. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003;61:1123-8
8. Ouslander JG. Management of overactive bladder. New Engl J Med 2004;350:786-99
9. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172(5 Pt 1):1919-24
10. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Br J Urol Int 2004;93:303-10
11. Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study, Br J Urol Int 2004;93:71-7
12. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the anti-muscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002;18:177-84
13. Preik M, Albrecht D, O'Connell M, et al. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. Br J Urol Int 2004;94:821-7
14. Landis JR, Kaplan S, Swift S, et al. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 2004;171(2 Pt 1):752-6
15. Data on file. Yamanouchi Pharmaceutical Co., Ltd
16. van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 1960;37:351-61
17. Chapple C, Cardozo L, Steers WD, et al. Solifenacin effectively improves all key symptoms of overactive bladder syndrome. Curr Med Res Opin 2005 [submitted for publication]
18. Cardozo L, Castro-Diaz D, Gittelman M, et al. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with Solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 2005 [submitted for publication]